Related Articles
Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit
Oncotype testing in patients undergoing intraoperative radiation for breast cancer
Oncotype DX 21‑gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma
Circulating cytokeratin 18 fragments and activation of dormant tumor cells in bone marrow of cancer patients (Review)
Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21‑gene recurrence score of 26‑30